Regeneron Pharmaceuticals Inc (REGN, Tarrytown, New York) have announced the receipt of FDA approval for their VEGF trap eye product (Eylea; VTE; aflibercept) for the treatment of macular edema following central retinal vein occlusion (CRVO). According to the company, the approval of the drug was based on data from Phase 3 studies. This is the second approval for Eylea and is expected to further expand the choice of available treatment regimens for the treatment of macular edema following CRVO.
Regeneron announces FDA approval for anti-VEGF Eylea to treat macular edema following CRVO
- by swdadmin